Second look reveals potential for Columbia Labs drug

After reporting last February that progesterone gel failed to hit its primary endpoint and all secondary endpoints for preventing preterm births, Columbia Laboratories says that a second look at the late-stage data showed evidence that the drug could delay cervical shortening, which increases preterm delivery risks.

"We are excited to share these unexpected findings, which may support the further development of Prochieve to prevent preterm birth in women with a short cervix," said CEO Robert Mills. That news helped propel the company's stock up 23 percent.

- check out the release on the new data

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.